Stockreport
Gilead Sciences (GILD) To Report Earnings Tomorrow: Here Is What To Expect [Yahoo! Finance]
Last gilead sciences, inc. earnings: 4/30 04:01 pm
Check Earnings Report
US:NASDAQ Investor Relations: investors.gilead.com
Gilead Sciences beat analysts' revenue expectations by 6.3% last quarter, reporting revenues of $7.57 billion, up 6.4% year on year. It was a very strong quarter for the company, with a solid beat of analysts' full-year EPS guidance estimates and an impressive beat of analysts' EPS estimates. Is Gilead Sciences a buy or sell going into earnings? Read our full analysis here, it's free This quarter, analysts are expecting Gilead Sciences's revenue to grow 1.3% year on year to $6.77 billion, slowing from the 5.3% increase it recorded in the same quarter last year. Adjusted earnings are expected to come in at $1.74 per share. Analysts covering the company have generally reconfirmed their estimates over the last 30 days, suggesting they anticipate the business to stay the course heading into earnings. Gilead Sciences has a history of exceeding Wall Street's expectations, beating revenue estimates every single time over the past two years by 3.6% on average. With Gilead Sciences be
[Read more]
| IMPACT SNAPSHOT | EVENT TIME: | GILD | ||||
|---|---|---|---|---|---|---|
|
Last Price
|
Price Change
|
Price Change %
|
Volume Shares
|
Max Up
|
Max Down
|
Volume Ratio
%
|
Performance comparison
Updated
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| LAST PRICE | ||
| VWAP | ||
|
High:
|
MAX UP |
High:
|
|
Low:
|
MAX DOWN |
Low:
|
|
%
|
POST NEWS RANGE |
%
|
|
|
PRICE CHANGE |
|
|
|
PRICE CHANGE PERCENTAGE |
|
|
|
S&P 500 (SPX) |
|
|
%
|
VOLUME RATIO |
%
|
| VOLUME (SHARES) | ||
| TICKS | ||
|
|
AVG SHARES PER TRADE |
|
Don't Miss Out On The Next BIG Stock Move
EVENT DAY
Event Day Chart will not be displayed beyond 90-day period of the event
PERFORMANCE SINCE EVENT
TIME AND VELOCITY ANALYSIS
Be the first to know
Opt in for alerts from News Quantifed
Opt-in for
GILD alerts
GILD alerts
from News Quantified
Movers & Shakers
The biggest gainers and losers and WHY it moved
GILD alerts
High impacting Gilead Sciences, Inc. news events
Weekly update
A roundup of the hottest topics
GILD
NEWS
NEWS
- Gilead Sciences Appoints Keeley Wettan as Executive Vice President, General Counsel, Legal & Compliance [Yahoo! Finance][Yahoo! Finance]
- Gilead Sciences Appoints Keeley Wettan as Executive Vice President, General Counsel, Legal & Compliance[Business Wire]
- Gilead's Investigational Single-Tablet Regimen of Bictegravir and Lenacapavir for HIV Treatment Meets Primary Endpoint in Phase 3 ARTISTRY-2 Trial [Yahoo! Finance][Yahoo! Finance]
- Gilead’s Investigational Single-Tablet Regimen of Bictegravir and Lenacapavir for HIV Treatment Meets Primary Endpoint in Phase 3 ARTISTRY-2 Trial[Business Wire]
- Gilead Sciences (NASDAQ:GILD) had its "outperform" rating reaffirmed by analysts at Wolfe Research.[MarketBeat]
- More
GILD
SEC Filings
SEC Filings
- 12/16/25 - Form 4
- 12/16/25 - Form 4
- 12/15/25 - Form 144
- GILD's page on the SEC website
- More